Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma

• Main Authors: Giulio Metro (Author), Diego Signorelli (Author), Elio G. Pizzutilo (Author), Laura Giannetta (Author), Giulio Cerea (Author), Miriam Garaffa (Author), Alex Friedlaender (Author), Alfredo Addeo (Author), Martina Mandarano (Author), Guido Bellezza (Author), Fausto Roila (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Unresectable malignant pleural mesothelioma (MPM) is an aggressive disease with a 5-year survival rate of approximately 10%. Recent data suggest that MPM is an immunologically active tumor, in which checkpoint inhibition through the blockade of the anti-cytotoxic T lymphocyte antigen-4 (-CTLA-4) or...